Ironwood Pharmaceuticals, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Amounts below are in U.S. dollars; financial statement amounts are in millions unless noted.
Business context
Ironwood is a gastrointestinal healthcare company. Its principal commercial product is LINZESS, marketed in the U.S. with AbbVie under a profit-and-loss sharing arrangement. Ironwood also receives international linaclotide royalties and is developing IW-3300 and CNP-104.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $97.2 | $104.0 | $194.8 | $192.9 |
| Operating income | $55.7 | $65.1 | $113.5 | $110.5 |
| Net income | $37.1 | $391.3 | $75.9 | $431.2 |
| Operating cash flow | $61.4 | $48.6 | $125.5 | $122.3 |
- Q2 operating margin was approximately 57%; six-month operating margin was approximately 58%.
- Q2 R&D expense was $11.5 million and SG&A was $30.1 million. For the first half, R&D was $22.3 million and SG&A was $59.0 million.
- At June 30, cash and cash equivalents were $504.4 million, with $1.7 million of restricted cash. Total assets were $975.7 million and stockholders’ equity was $532.9 million.
- Ironwood repaid the $120.7 million principal balance of its 2022 convertible notes at maturity in June. Remaining convertible notes had $400 million aggregate principal due in 2024 and 2026; their net carrying value was $395.5 million. Cash exceeded their principal by approximately $104 million.
- First-half cash declined $115.8 million, primarily reflecting $120.7 million of note repayment and share repurchases. Investing cash outflow was immaterial.
Changes versus the prior comparable period
- Q2 revenue fell 7%, primarily because Ironwood’s U.S. LINZESS profit share declined with lower net price and inventory fluctuations, partly offset by higher prescription demand. First-half revenue increased 1%, with higher demand partly offset by lower net price.
- Operating income declined in Q2, while first-half operating income increased modestly. SG&A rose 11% in Q2 and 8% in the first half, including higher compensation and marketing costs; R&D declined 6% and 19%, respectively, largely as IW-3718 costs decreased and IW-3300 investment increased.
- Net income comparisons are dominated by the 2021 release of a tax valuation allowance, which generated a $337.8 million discrete tax benefit. Ironwood recorded tax expense of $16.7 million in Q2 2022 and $34.4 million in the first half of 2022; most was expected to be non-cash while tax losses are used.
- Adoption of ASU 2020-06 reduced reported non-cash interest expense. The company reported interest expense of $2.2 million in Q2 2022 versus $7.7 million in Q2 2021, and $4.5 million versus $15.4 million for the first half.
Outlook, risks and unusual items
- Management said cash on hand at June 30 was expected to fund projected operating needs for at least the next 12 months, alongside expected operating cash inflows. It also cautioned that actual cash use could exceed estimates.
- Ironwood expected to initiate a Phase 2 proof-of-concept study of IW-3300 in IC/BPS by the end of 2022. CNP-104 clinical data were estimated for 2023; Ironwood retains an option to license the program and would owe additional payments if exercised.
- Revenue is highly dependent on the AbbVie U.S. LINZESS collaboration. Results can vary with prescription demand, net price, inventory, commercial expenses and settlement calculations; Ironwood relies on AbbVie for sales information used in its accounting.
- Management cited clinical and regulatory uncertainty, competition, manufacturing and supply risks, reimbursement, intellectual-property matters, and possible ongoing COVID-19 effects on promotion, healthcare access and sales. COVID-19 had not significantly disrupted U.S. LINZESS supply as of the filing.
- The $150 million share-repurchase program was completed in May 2022: 13.1 million shares were repurchased at an average $11.47 per share and retired. Note hedge warrants related to the matured 2022 notes remained outstanding and could dilute shares if the stock price exceeds their $18.82 strike price.
- The company reported effective disclosure controls and no material changes in internal control over financial reporting. It disclosed no material changes to the risk factors in its 2021 Form 10-K.
Important facts for investors to verify
- Trends in U.S. LINZESS prescription demand, net pricing, inventory and AbbVie settlement calculations.
- Cash generation and spending relative to management’s stated 12-month liquidity outlook, including any CNP-104 option exercise or development spending.
- Progress and timing of the IW-3300 Phase 2 study and CNP-104 data readout.
- Terms, settlement and potential dilution associated with the 2024 and 2026 convertible notes, and the remaining note hedge warrants.
- Tax expense and use of deferred tax assets, given the substantial non-recurring tax benefit in the 2021 comparison period.